As metabolic disease quietly overtakes hepatitis B as the leading driver of cirrhosis in Singapore, the country's Health Sciences Authority has approved semaglutide — marketed as Wegovy — as the first pharmacological treatment for metabolic dysfunction-associated steatohepatitis with liver fibrosis. The decision reflects a broader reckoning: the diseases of modern abundance are now reshaping the burden of advanced liver illness across Asia. Where fatty liver once seemed a silent inconvenience, it has become a measurable force behind cirrhosis and liver cancer, and medicine is only beginning to
Singapore Approves Wegovy as First MASH Treatment, Showing 63% Steatohepatitis Resolution
The disease progresses without obvious warning signs
Mark
So semaglutide—the weight-loss drug—is now approved for liver disease in Singapore. How does a drug for weight loss become a liver treatment?
Mimi
It's not really a weight-loss drug being repurposed. Semaglutide works on metabolic dysfunction at a deeper level. MASH is driven by metabolic dysfunction—obesity, insulin resistance, inflammation. Semaglutide addresses those root causes, and when you do that, the liver inflammation and scarring can improve.
Luke
But we should be clear: the trial showed improvement in inflammation and fibrosis markers at 72 weeks. We don't yet know if it prevents cirrhosis or liver failure. That's what the 240-week follow-up is meant to answer.
Mark
The numbers are pretty striking—63 percent versus 34 percent on placebo. Is that the kind of difference that changes clinical practice?
Mimi
It's significant enough that Singapore's regulator approved it as a first-line option. And the fact that a third of patients achieved both resolution of inflammation and fibrosis improvement—that's not trivial. But Luke's right: we're looking at intermediate outcomes, not hard clinical events yet.
Luke
And we should note the trial is still ongoing. These are interim results. The full picture might look different at 240 weeks.
Mark
What struck me most was the shift in Singapore's cirrhosis causes. MASH is now 40 percent, hepatitis B is 23 percent. That's a real change in the disease landscape.
Mimi
It reflects what's happening globally—metabolic disease is rising faster than infectious disease as a driver of advanced liver disease. That's partly obesity, partly diabetes prevalence. It's a public health signal.
Luke
Though we should note that's based on one registry of 1,200 people in Singapore. It's real data, but it's not a population-wide survey. It's a snapshot of who's presenting with cirrhosis, not necessarily the full epidemiology.
Mark
Fair. So what happens next?
Mimi
Clinicians in Singapore now have a treatment option. The question is whether they use it early enough—before fibrosis becomes too advanced—and whether they combine it with the lifestyle changes that are still the foundation.
Luke
And we wait for the long-term data. Intermediate markers are one thing. Preventing cirrhosis and liver failure is another.
Le Pouls
- MASH has surpassed hepatitis B as the leading cause of cirrhosis in Singapore, now accounting for nearly 40% of cases — a shift that caught many clinicians off guard.
- The disease advances without obvious symptoms, meaning patients with obesity or diabetes may carry significant liver scarring long before any warning sign appears.
- Phase 3 trial data showed semaglutide nearly doubled the rate of steatohepatitis resolution compared to placebo — 63% versus 34% — offering the first approved pharmacological foothold against the disease.
- Singapore's approval opens a new treatment pathway, but the drug is positioned as an adjunct to lifestyle change, not a replacement for diet and physical activity.
- The ESSENCE trial continues to 240 weeks, leaving the most consequential questions — whether semaglutide prevents cirrhosis and liver-related clinical events — still unanswered.
As metabolic disease quietly overtakes hepatitis B as the leading driver of cirrhosis in Singapore, the country's Health Sciences Authority has approved semaglutide — marketed as Wegovy — as the first pharmacological treatment for metabolic dysfunction-associated steatohepatitis with liver fibrosis. The decision reflects a broader reckoning: the diseases of modern abundance are now reshaping the burden of advanced liver illness across Asia. Where fatty liver once seemed a silent inconvenience, it has become a measurable force behind cirrhosis and liver cancer, and medicine is only beginning to answer.
Singapore's Health Sciences Authority has approved Wegovy — the once-weekly injectable form of semaglutide — as the country's first approved treatment for adults with metabolic dysfunction-associated steatohepatitis, or MASH, accompanied by moderate to advanced liver scarring. The decision marks a clinical turning point in a region where the pattern of serious liver disease is changing faster than many expected.
The approval rests on data from the ESSENCE trial, a phase 3 study comparing semaglutide against placebo in patients with noncirrhotic MASH and fibrosis at stages F2 or F3. At 72 weeks, 63 percent of those receiving semaglutide achieved resolution of inflammatory liver damage without fibrosis worsening, against 34 percent on placebo. When both steatohepatitis resolution and fibrosis improvement were required simultaneously, a third of semaglutide recipients cleared that bar — compared to just 16 percent on placebo.
MASH is the progressive form of fatty liver disease, in which excess fat accumulates alongside metabolic dysfunction — obesity, type 2 diabetes, related conditions — and then inflammation and cellular injury take hold. The scarring that follows can advance silently toward cirrhosis and liver cancer. Singapore's own registry data make the stakes concrete: MASH now accounts for 39.8 percent of cirrhosis cases in the country, while hepatitis B — long the dominant driver of advanced liver disease across Asia — has fallen to 23.5 percent.
Clinicians note that the disease's silence is part of what makes it dangerous. Patients with metabolic risk factors may carry significant liver damage without any outward sign, making early identification critical. Semaglutide's side effect profile in MASH patients mirrors its known profile elsewhere, with gastrointestinal effects being most common, and the drug is intended to complement — not replace — lifestyle interventions.
The ESSENCE trial continues to 240 weeks, with researchers tracking whether semaglutide can reduce liver-related clinical events and prevent progression to cirrhosis. That longer-term evidence will determine how broadly and confidently the drug enters clinical practice. For now, Singapore has established the first approved treatment pathway for a disease that is becoming increasingly difficult to overlook.
Singapore's Health Sciences Authority has approved Wegovy—the once-weekly injectable form of semaglutide at 2.4 milligrams—as the first treatment in the country for adults with metabolic dysfunction-associated steatohepatitis, or MASH, paired with moderate to advanced liver scarring. The approval marks a clinical milestone in a region where the disease landscape is shifting faster than many clinicians expected.
The decision rests on data from the ESSENCE trial, a phase 3 study that ran to week 72 and compared semaglutide against placebo in patients with noncirrhotic MASH and fibrosis stages F2 or F3. The results were substantial. Among those receiving semaglutide, 63 percent achieved resolution of the inflammatory liver damage without their fibrosis worsening, compared to 34 percent on placebo. When the bar was raised—requiring both steatohepatitis resolution and at least one stage of fibrosis improvement—37 percent of the semaglutide group cleared it versus 22 percent on placebo. A third of semaglutide recipients achieved both endpoints simultaneously; only 16 percent of placebo recipients did.
MASH itself is the progressive, dangerous cousin of fatty liver disease. It begins when excess fat accumulates in the liver alongside metabolic dysfunction—obesity, type 2 diabetes, and related conditions—but then inflammation and cellular injury take hold. The scarring that follows, fibrosis, can advance silently. Without intervention, the disease moves toward cirrhosis and liver cancer. Globally, the age-standardized prevalence of the broader fatty liver category increased 11.2 percent between 2010 and 2021, a climb that reflects rising metabolic disease worldwide.
Singapore's own data underscore why this approval matters locally. The SingHealth Chronic Liver Disease Registry, which tracks nearly 1,200 people with cirrhosis, showed that MASH accounted for 39.8 percent of cirrhosis cases in 2024. Hepatitis B, long the dominant driver of advanced liver disease in Asia, now represents only 23.5 percent. The shift is real and measurable. Dr. Kieron Lim, a senior gastroenterologist and president of the Gastroenterological Society of Singapore, noted that the disease progresses without obvious warning signs, meaning patients with obesity, diabetes, or other metabolic risk factors may harbor significant liver damage without knowing it. The clinical task, he emphasized, is not simply detecting fat in the liver but identifying whether inflammation and scarring have begun—and acting before the damage becomes irreversible.
The approval comes with a standard safety caveat: semaglutide's adverse reaction profile in MASH patients mirrors what has been observed in other approved uses, with gastrointestinal effects, particularly nausea, being the most frequently reported. The drug is intended as an adjunct to lifestyle change—reduced-calorie diet and increased physical activity remain foundational.
The ESSENCE trial itself continues. Researchers are following participants out to 240 weeks to determine whether semaglutide reduces the risk of liver-related clinical events and whether it can prevent progression to cirrhosis. That longer-term data will shape how widely and confidently the drug is used in clinical practice. For now, Singapore has opened a new treatment pathway for a disease that is becoming harder to ignore.
Citations marquantes
MASH can progress quietly. People with obesity, type 2 diabetes or other metabolic risk factors may need a more complete liver assessment even if they feel well.— Dr. Kieron Lim, Senior Consultant Gastroenterologist and President of Gastroenterological Society of Singapore
Envie de l'histoire complète ?
Lire l'original sur BioPharma APAC ↗
Health & Medicine